Neurocrine Biosciences To Present At The Leerink Global Healthcare Conference

Neurocrine Biosciences To Present At The Leerink Global Healthcare Conference

Live Audio Webcast will be on February 12, 2014

PR Newswire

SAN DIEGO, Feb. 7, 2014

SAN DIEGO, Feb. 7, 2014 /PRNewswire/ --Neurocrine Biosciences, Inc. (Nasdaq:
NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine
Biosciences, will be presenting at the Leerink Global Healthcare Conference in
New York City.

The live presentation takes place on Wednesday, February 12 at 10:15am ET
(7:15am PT). The presentation will be webcast and may be accessed on the
Company's website at http://www.neurocrine.com. 

Listeners are encouraged to visit the website approximately 5 minutes prior to
the presentation to download or install any necessary software. A replay of
the presentation will be available on the website approximately one hour after
the conclusion of the event and will be archived for one month.

Neurocrine Biosciences, Inc. is a clinical stage drug discovery company
primarily focused on neurological and endocrine based diseases and disorders.
The Company discovers and develops innovative pharmaceuticals, in diseases
with high unmet medical needs or where the existing drug classes are
inadequate, through a disciplined yet entrepreneurial process. Utilizing a
portfolio approach to drug discovery, Neurocrine has multiple small molecule
drug candidates at various stages of pharmaceutical development. Neurocrine's
two lead late stage clinical programs are elagolix, a GnRH antagonist for
women's health that is partnered with AbbVie Inc., and a wholly owned VMAT2
inhibitor for the treatment of movement disorders. Neurocrine intends to
maintain certain commercial rights to its VMAT2 inhibitor for evolution into a
fully-integrated pharmaceutical company. Neurocrine Biosciences, Inc. news
releases are available through the Company's website via the internet at
http://www.neurocrine.com.

SOURCE Neurocrine Biosciences, Inc.

Website: http://www.neurocrine.com
Contact: Investor Relations, (858) 617-7600
 
Press spacebar to pause and continue. Press esc to stop.